Black Diamond Therapeutics Business Summary

Black Diamond Therapeutics, Inc. (BDTX) is a clinical-stage precision oncology company that operates on a business model centered on the discovery and development of "MasterKey" therapies. The company generates revenue primarily through strategic asset monetization and high-value licensing collaborations, exemplified by its 2025 agreement with Servier Pharmaceuticals for the RAF inhibitor BDTX-4933, which included a $70 million upfront payment. Its primary business segments are focused on its proprietary Mutation-Allostery-Pharmacology (MAP) platform, which identifies and targets families of oncogenic mutations rather than single-point mutations. The company's lead clinical candidate, silevertinib (BDTX-1535), is a brain-penetrant EGFR inhibitor targeting non-small cell lung cancer (NSCLC) and glioblastoma. In the competitive landscape, Black Diamond contends with precision oncology firms such as Keros Therapeutics, ADC Therapeutics, and Agios Pharmaceuticals, positioning itself as a specialist in brain-penetrant small molecules designed to overcome resistance mechanisms in genetically defined solid tumors. The company was co-founded by Elizabeth Buck, Ph.D., and David M. Epstein, Ph.D., both of whom possess deep pedigrees in oncology drug discovery from OSI Pharmaceuticals. The current leadership team is headed by President and CEO Mark Velleca, M.D., Ph.D., who previously served as CEO of StrideBio and co-founder of CGI Pharmaceuticals (acquired by Gilead). Supporting the executive suite are Chief Scientific Officer Elizabeth Buck, Chief Medical Officer Sergey Yurasov, M.D., Ph.D., and Chief Operating Officer Brent Hatzis-Schoch. The company is backed by a sophisticated roster of institutional investors, including New Enterprise Associates (NEA), RA Capital Management, and Boxer Capital. Its Board of Directors features prominent industry figures such as Samarth Kulkarni (CEO of CRISPR Therapeutics) and Ali Behbahani of NEA, providing a robust governance framework for its clinical-stage pipeline.